Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics using its proprietary lipid nano-crystal (LNC) delivery platform. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on improving the delivery and efficacy of existing drugs while reducing toxicity. Its core strategic objective has been to apply its technology to both antifungal and anti-infective therapies, addressing serious unmet medical needs.
The company’s historical lead program was MAT2203, an orally delivered formulation of amphotericin B, designed to treat invasive fungal infections while avoiding the toxicity associated with intravenous administration. Matinas was founded in 2013 and became publicly listed in 2014. Over time, the company has evolved from a single-asset focus toward exploring broader applications of its LNC platform, while also managing financial constraints typical of small-cap clinical-stage biotechnology firms. As of the most recent public disclosures, the company has significantly reduced active clinical development while evaluating strategic alternatives.
Business Operations
Matinas BioPharma does not generate commercial product revenue and has historically relied on equity financing, grants, and strategic collaborations to fund operations. Its business model centers on research and development activities, including preclinical studies, clinical trials, and regulatory engagement. The company’s primary operating segment is biopharmaceutical research and development, with expenditures largely allocated to clinical trials, manufacturing scale-up, and intellectual property maintenance.
The company’s core asset is its proprietary LNC drug delivery technology, which it controls and has patented. Matinas has previously engaged in collaborations and supply agreements related to antifungal research, though it does not currently report large-scale joint ventures or revenue-generating partnerships. Operations are primarily domestic, with clinical and regulatory activities extending internationally through trial sites and manufacturing partners.
Strategic Position & Investments
Strategically, Matinas BioPharma has focused on leveraging its LNC platform to reformulate existing drugs with known efficacy but limited usability due to toxicity or delivery challenges. Its most significant investment historically was in the clinical development of MAT2203, which progressed through multiple clinical studies. However, mixed clinical outcomes and capital limitations have led the company to reassess its development pipeline and reduce operating scope.
The company has not completed any major acquisitions and does not maintain a diversified portfolio of subsidiaries. Instead, its strategic positioning has centered on intellectual property ownership and the optionality of partnering or licensing its technology. Emerging applications of the LNC platform, including potential uses beyond antifungal indications, have been discussed in corporate communications, though advancement has been constrained by funding availability.
Geographic Footprint
Matinas BioPharma is headquartered in the United States, with its principal executive offices in New Jersey. The company’s operational footprint is primarily domestic, reflecting its size and clinical-stage focus. Research, management, and administrative functions are concentrated in the U.S., while certain manufacturing and clinical trial activities have involved international vendors and study sites.
Although Matinas does not maintain permanent international offices, its clinical development programs have historically involved regulatory engagement and trial execution across multiple regions, including North America and Europe, depending on study design. Its global footprint is therefore best characterized as operationally international but organizationally centralized in the U.S.
Leadership & Governance
Matinas BioPharma is led by an experienced management team with backgrounds in pharmaceuticals, biotechnology, and corporate finance. Leadership has emphasized capital discipline, platform-driven innovation, and strategic flexibility in response to clinical and market developments. The board of directors provides governance oversight typical of a publicly traded biotechnology company, including audit, compensation, and governance committees.
Key executives include:
- Jerome D. Jaffe – Chief Executive Officer
- William S. Peters – Chief Financial Officer
- David McCurdy – Chief Operating Officer
- Michael J. Palecek – Chief Scientific Officer
The leadership team’s stated strategic vision has centered on maximizing the value of the company’s technology platform while responsibly managing shareholder capital in a challenging small-cap biotechnology environment.